A PYMNTS Company

US: Johnson & Johnson secures $1.75B takeover

By  |  October 1, 2014

Leading pharmaceutical conglomerate Johnson & Johnson announced that it has reached an agreement to acquire Alios BioPharma for about $1.75 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, J&J’s takeover of the biopharmaceutical company will expand its portfolio of medications used to treat viral infections. Alios currently owns a compound in Phase II trials to treat infants with respiratory syncytial virus, the last major pediatric disease with no preventative therapy, according to reports.

    The takeover remains subject to regulatory approval, though the companies expect to complete the takeover in the fourth quarter of this year.

    Full content: Pharmaceutical Business Review

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.